Open AccessA Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
Author(s) -
Emil H. Schemitsch,
Theodore Miclau,
Theofilos Karachalios,
L Nowak,
Parag Sancheti,
Rudolf W. Poolman,
John Caminis,
Nadia Daizadeh,
Ricardo E Dent-Acosta,
Ogo Egbuna,
Arkadi Chines,
Judy Maddox,
Andreas Grauer,
Mohit Bhandari
Publication year - 2020
Publication title -
journal of bone and joint surgery. american volume/the journal of bone and joint surgery. american volume
Language(s) - English
Resource type - Journals
eISSN - 1058-2436
pISSN - 0021-9355
DOI - 10.2106/jbjs.19.00790
Subject(s) - medicine , placebo , tolerability , clinical endpoint , randomized controlled trial , surgery , adverse effect , pathology , alternative medicine
Romosozumab is a bone-forming antibody that increases bone formation and decreases bone resorption. We conducted a double-blinded, randomized, phase-2, dose-finding trial to evaluate the effect of romosozumab on the clinical outcomes of open reduction and internal fixation of intertrochanteric or femoral neck hip fractures.